Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: INCB007839|DRUG: INCB007839|DRUG: INCB007839|DRUG: INCB007839|DRUG: trastuzumab|DRUG: Docetaxel
Sponsor: Incyte Corporation